SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001178913-23-003115
Filing Date
2023-09-11
Accepted
2023-09-11 12:38:47
Documents
2
Group Members
I.B.F MANAGEMENT LTD.ISRAEL BIOTECH FUND GP PARTNERS I, L.P.ISRAEL BIOTECH FUND GP PARTNERS II, L.P.ISRAEL BIOTECH FUND II, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D zk2330283.htm SC 13D 228868
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 10108
  Complete submission text file 0001178913-23-003115.txt   240864
Mailing Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852
Business Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852 732 545 1590
Ayala Pharmaceuticals, Inc. (Subject) CIK: 0001100397 (see all company filings)

IRS No.: 841521955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-80101 | Film No.: 231247267
SIC: 2834 Pharmaceutical Preparations

Mailing Address HANNAH RUBINA 11 TEL AVIV L3 6937215
Business Address HANNAH RUBINA 11 TEL AVIV L3 6937215 972-52-873-9833
Israel Biotech Fund I, L.P. (Filed by) CIK: 0001652458 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D